We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Quantum Phar. | LSE:QP. | London | Ordinary Share | GB00BRTL8Q42 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 84.2374 | 84.00 | 84.75 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
05/8/2016 07:20 | Yes and good to think that some products are available for these poor people. | hazl | |
05/8/2016 07:12 | from todays RNS: "Whilst it is relatively early following the launch of the range, and as such we are still in the market access phase, the initial response from clinical teams at hospitals has been encouraging, and the use in their units has provided favourable patient feedback. We are positive on the outlook for the range over the short to medium term." | cougar99 | |
03/8/2016 06:16 | and a nice upward thrust in share price yesterday .... QP making progress in a slow but sure way .... keep making the medicine and look forward to the future .... | cougar99 | |
01/8/2016 11:22 | Good to see Oryx International Growth Fund buying and going above 3% with 3.78m shares: | rivaldo | |
27/7/2016 09:27 | I don't think they are a bad little firm and they have regular demand. IMO | hazl | |
26/7/2016 21:33 | absolutely dacian just to qualify I don't have great quantities in anything at present. | hazl | |
26/7/2016 15:38 | N+1 Singer's forecasts are currently: this year : 6.5p EPS, 1.8p dividend next year : 7.6p EPS, 2.3p dividend I got hold of their note from May, which concluded: "Shares remain undervalued The shares continue to look heavily oversold, standing on a Jan-17 P/E of just 9.4x. We see the current valuation as being underpinned by the Specials business, with the Niche Pharmaceuticals and Medication Adherence activities effectively in for nothing. We see an intrinsic valuation range of 97-132p based on a peer group analysis and a DCF." | rivaldo | |
26/7/2016 12:01 | YES I believe its just having a breather after a rise. Trend LOOKS UP from where I am standing....higher lows....and so on IMO | hazl | |
26/7/2016 08:59 | But consistently failed to meet targets. | r ball | |
26/7/2016 08:39 | Drifting. Needs CEO in place and renewed confidence. Cannot see many lining up to take the job. | r ball | |
26/7/2016 08:05 | Far too much information for me on this occasion in the RNS | davr0s | |
26/7/2016 08:00 | Perhaps the share price will bottom out? | busterdog2 | |
26/7/2016 07:43 | Blimey, I see QP.'s latest product relates to addressing a very unpleasant condition. | shanklin | |
21/7/2016 19:42 | Couple chunky buys but made no difference to price (yet) | davr0s | |
21/7/2016 08:00 | Front page headlines in the Times today too. Free advertising! | busterdog2 | |
21/7/2016 04:27 | Just what the Doctor ordered, albeit in small doses: Vitamin D supplements 'advised for everyone' | cougar99 |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions